{"page":"https://casescribe.ai/explorer/regulation-changes/2026-08-24","generated_at":"2026-10-03T18:33:41.087Z","data_as_of":{"decisions":944125,"first_year":2017,"last_year":2026,"latest_decision":"2026-04-30","cfr":"2026-10-01","m21":"2026-09-29"},"about":{"publisher":"CaseScribe AI (VA Law Explorer)","source":"Public Board of Veterans' Appeals decisions (appeals of VA decisions, not VA's first decisions), M21-1 Adjudication Procedures Manual, 38 CFR Parts 3 and 4.","method":"Outcomes are issue-level: each condition the Board decided in a decision counts once. Decision data is extracted by AI and can contain errors. Rates describe past appeals and do not predict any claim.","disclaimer":"For research only. CaseScribe AI is not a law firm and this is not legal advice. Verify figures against the source decisions and regulations.","attribution":"Cite as: VA Law Explorer, CaseScribe AI, with the page URL."},"data":{"week_of":"2026-08-24","changes":[{"source":"M21-1","section":"Part V, Subpart iii, Chapter 8, Section B - Disabilities of the Breast","date":"2026-08-27","url":"https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180879/M21-1-Part-V-Subpart-iii-Chapter-8-Section-B-Disabilities-of-the-Breast","formatting_only":false,"added":["Use the table below to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted, as well as the proper DC to use in the evaluation.","residuals of surgery under appropriate DC(s) including","series for scars, and/or","a nexus between the fibrocystic breasts with associated atypical hyperplasia and the development of breast cancer","breast cancer and/or residuals under appropriate DC(s) including",", no more than a noncompensable evaluation can be assigned as there is no significant alteration in size or form, since the removal of excess tissue results in a return to breast size within normal limits for a human male."],"removed":["Use the table below to determine when SC for pathology associated with claimed fibrocystic breast disease is warranted as well as the proper DC to use in the evaluation.","residuals of surgery under appropriate DCs including","series for scars, and","nexus between the fibrocystic breasts with associated atypical hyperplasia and the development of breast cancer","breast cancer and/or residuals under appropriate DCs including",", no more than a noncompensable evaluation can be assigned as there is no significant alteration in size or form since the removal of excess tissue results in a return to breast size within normal limits for a human male."]},{"source":"M21-1","section":"Part I, Subpart i, Chapter 1, Section B - General Information on Due Process","date":"2026-08-26","url":"https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000181468/M21-1-Part-I-Subpart-i-Chapter-1-Section-B-General-Information-on-Due-Process","formatting_only":false,"added":["due process and",", and","Field Examiners","Legal Instrument Examiner (LIE), and","beneficiary’s survivors","Notices from Field Examiners may be considered first party notices when reported on a fully complete","other possible sources","computer application used by VA."],"removed":["due process and the","due process and VA","Field examiners","Legal instrument examiner (LIE), and","Beneficiary’s survivors","Notices from field examiners may be considered first party notices when reported on a fully complete","Other possible sources","Share computer application."]}]}}